Effectiveness and safety of azithromycin 1.5% eye drops for mass treatment of active trachoma in a highly endemic district in Cameroon

Assumpta Lucienne Bella,1 Ellen Einterz,2 Pierre Huguet,3 Philippe Bensaid,4 Abdou Amza,5 Didier Renault

ABSTRACT

Objective To evaluate the effectiveness and safety of azithromycin 1.5% eye drops under field conditions to reduce active trachoma in a highly endemic district in Cameroon. This is a follow-up of an initial report published in 2010.

Methods and analysis Three annual campaigns were performed in 2008, 2009 and 2010 to treat the population (~120 000 individuals) of the Kolofata Health District with topical azithromycin 1.5% (one drop in each eye, morning and evening for three consecutive days). The effectiveness of this intervention against active trachoma was assessed in children aged 1–9 years in cross-sectional studies prior to each mass treatment using a systematic sampling procedure (in 2008, 2009 and 2010) and then 1 year (2011) and 3 years (2013) after the last intervention among the villages with previously high active trachoma prevalence or never tested.

Results The prevalence of trachomatous inflammation—follicular (TF) dropped from 24.0% (95% CI 20.7 to 27.5) before treatment to 2.8% (95% CI 2.2 to 3.7) 1 year after completion of the 3-year campaign. Trachomatous inflammation—intense was present in only 4 (0.2%) children 1 year after the third round of treatment. Three years after the last campaign, the surveillance survey among the most prevalent villages and villages never tested before showed a prevalence of 5.2% (95% CI 3.6 to 7.2) of active trachoma. Tolerance was excellent, with no report of treatment interruption, serious ocular or systemic adverse events.

Conclusion Annual mass treatment with azithromycin eye drops was shown to be effective in reducing TF to a level ≤5% one year after a 3-round annual mass treatment in an endemic region at the district level.

INTRODUCTION

Trachoma is a chronic infectious condition of the eye caused by the microorganism Chlamydia trachomatis. It is the leading infectious cause of blindness worldwide and was previously estimated to be responsible for visual impairment in 1.6 million individuals, of which 0.4 million were irreversibly blind.4 The disease begins in early childhood. It is seen mostly in children in association with red, sticky eyes, with symptoms of itchy, painful eyes. In the WHO simplified system, the two defined signs of active trachoma are trachomatous inflammation—follicular (TF, defined as the presence of five or more follicles measuring at least 0.5 mm in diameter in the upper tarsal conjunctiva) and trachomatous inflammation—intense (TI, defined as pronounced inflammatory thickening of the tarsal conjunctiva that obscures more than half of the normal tarsal vessels).5 Repeated inflammation from cycles of infection and reinfection causes entropion, trichiasis, corneal abrasion and corneal opacity which may lead to blindness.3 4 The disease is associated with poor sanitation and inadequate water access.5 Transmission occurs mainly by
close contact at home, both directly (via contaminated hands) and indirectly (via clothing, other contaminated materials or the bodies of eye-seeking flies).34

In 1993, the WHO endorsed a multifaceted strategy (SAFE) for the elimination of trachoma as a public health problem.6 In 1996, WHO launched the WHO Alliance for the Global Elimination of Trachoma by the year 2020 (GET2020), a partnership which supports country implementation of the SAFE strategy and the strengthening of national capacity through epidemiological assessment, monitoring, surveillance, project evaluation and resource mobilisation. The 'SAFE strategy' comprises Surgery for trachomatous trichiasis; Antibiotics to clear ocular C. trachomatis infection; Facial cleanliness and Environmental improvement to reduce transmission (particularly access to water and sanitation). The A, F and E should be delivered to entire endemic districts (usually populations of 100,000–250,000 inhabitants). The threshold for annual mass treatment with antibiotics was set at 10% prevalence. If TF prevalence was 10% or more, the whole district should be mass treated with antibiotics. If it was between 5% and 10%, then treatment should only be implemented at the community level.8 The global recommendation was to conduct annual mass treatments for a minimum of 3 years. These treatments must not be stopped until the TF level among children aged 1–9 had fallen below 5%. In the report of the 3rd Global Scientific Meeting on Trachoma, WHO recommended trachoma assessment at the subdistrict or village level when the TF prevalence fell below 10% in 1–9 years old children.9 In more recent years, the recommendation has been taken as permission to treat all residents of districts in which the TF prevalence is 5%–9.9%.10

Mass treatment campaigns for the prevention of blindness due to trachoma have been run using oral azithromycin, and numerous community-based trials have provided evidence that such treatment reduces the prevalence of active trachoma and ocular chlamydia infection.11 Using this strategy, several endemic countries have reported the elimination of trachoma as a public health problem during the last decade.12 Africa remains the most endemic region in the world, and it was recently estimated that more than 117 million people in the WHO African region (87% of all cases in the world) warranted treatment with the antibiotics, facial cleanliness and environmental improvement. In the Republic of Cameroon, the prevention of blindness and visual impairment represents one of the public health priorities of the Ministry of Public Health.13 In December 2006, a study assessing the prevalence of active and scarring trachoma in the Kolofata Health District (in Far North Cameroon) signalled the presence of endemic trachoma with significant blinding potential.13 14 Subsequently, The National Blindness Control Programme decided to plan an elimination programme by implementing the WHO-SAFE strategy and performing mass treatment of the entire district population.

A randomised, controlled, double-masked, double-dummy study in children aged 1–10 years old with active trachoma previously showed that azithromycin 1.5% eye drops (one drop in each eye, morning and evening for three consecutive days) was as efficient as oral azithromycin to resolve active trachoma at 60 days.15 It was thus decided to use topical azithromycin 1.5% to reduce the prevalence of active trachoma in the Kolofata Health District. First results of the impact surveys showed reduction of active trachoma below 5% 1 year after the second round of mass treatment with azithromycin eye drops.16 17 Here, we additionally report the effectiveness and safety results 1 year and 3 years after completion of the 3-year mass campaign.

METHODS
Mass treatment campaigns
Three annual mass treatments of all people living in the Kolofata Health District were implemented in 2008, 2009 and 2010 by the Cameroon Health Authorities, in partnership with the non-governmental organisation Ophthalmo Sans Frontières (OSF) and Laboratoires Théa (Clermont-Ferrand, France).

An exhaustive door-to-door census of all residents of the District (about 112,000 people) was conducted by 250 local, community-trained health workers, each assigned to a village or neighbourhood of 400–500 residents. The objective was to treat the entire population, including children less than 1 year old, with azithromycin 1.5% eye drops donated by Laboratoires Théa, as one drop in each eye, morning and evening for 3 consecutive days. The treatment administration was performed by the same community health workers under the supervision of an ophthalmic nurse during a 2-week period. A briefing was organised in Kolofata Hospital each evening where ophthalmic nurses reported the assessment of the mass treatment, including questionnaires intended to document any side effects or symptoms of the eye drops.

Prevalence surveys
The objective of this study was to assess the effectiveness of community-based treatment with 3 days of azithromycin eye drops in reducing the prevalence of active trachoma in children aged 1–9 years (≥1 year and up to their 10th birthday). Five cross-sectional prevalence studies at 1-year intervals were planned to assess active trachoma in children aged 1–9 years in 2008 (prior to the first mass treatment), 2009 (prior the second mass treatment), 2010 (prior to the third and last mass treatment), 2011 (1 year after the last mass treatment) and 2013 (3 years after the last mass treatment).

Prevalence surveys before mass treatment (2008, 2009 and 2010)
From the 2006 survey data,13 the internal cluster (ie, within village) correlation was estimated at 0.034. Assuming a prevalence of about 5% at the end of the third year, it was necessary to include 40 villages with at least 60 evaluable children per village, that is, 2400 children, to get a 95%
CI with a half-length of 1.5%. Thus, 40 villages (or neighbourhoods) were selected systematically using probability proportional to size. Within the selected cluster (village or neighbourhood), all households were identified and numbered, and all their members were registered based on the local census listing. Then, an initial house was randomly selected. A sampling interval (randomly chosen before the beginning of the study) identified the following houses to be included in the sample. The sampling continued until it achieved selection of 60 children aged between 1 and 9 years of age who had lived for at least 6 months in the village on the day of the survey. If a family had left the community for over 6 months and the house was empty on the day of the survey, the house was replaced by the nearest one. In the case of an empty household or of a missing child among the randomly selected, the survey team had to repeat their visit three times to check for the presence of the selected child. If after the third visit, the selected child could not be met, he or she was considered absent and not replaced.

Impact survey and surveillance survey after treatment cessation (2011 and 2013)
An impact survey was performed 1 year after the third mass treatment campaign (2011) and the surveillance survey was conducted 3 years after the last campaign (2013). Although 40 villages were randomly selected in 2008, 2009, 2010, it was shown that active trachoma was more prevalent in some villages or families. For the 2011 and 2013 surveys, since there was no clear recommendation on how to perform the surveillance survey, it was deemed acceptable to focus on communities or villages with a higher risk of trachoma, as stated in the 3rd WHO Global Scientific Meeting (2010) and the WHO Strategic and Technical Advisory Group in 2018. Consequently, we used the two-stage sampling within each of two parallel sampling approaches in the same district: the previously high prevalence villages in the previous surveys, and the previously non-sampled villages. This was done based on the lot quality assessment sampling, a method previously proposed by Myatt et al for a rapid assessment of prevalence of active trachoma. The other sample was composed of children from households never sampled, thus taking into account possible residual infection among villages never tested before.

Clinical assessments of active trachoma
TF and TI were separately assessed using the WHO simplified grading system. Active trachoma was assessed based on TF prevalence alone in line with the WHO recommendations. The prevalence of TI was considered as a secondary criterion.

All children enrolled in the study were examined by a senior ophthalmic nurse and/or an ophthalmologist. The examiner everted the upper eyelid and inspected the conjunctiva by means of a 2.5× magnifying glass and a torch held by an assistant in charge of recording the data. Before examining the next child, the examiner verified that the assistant had filled out the study sheet in accordance with study protocol guidelines. After a 4-day training session, prior to the study, each examiner was tested on 50 children with and without trachoma. Following evaluation, the inter-grader variation for TF and TI was almost perfect comparing each examiner to the reference grader (kappa scores between 0.81 and 1.00).

Assessment of safety
Drug-related serious adverse events were assessed and recorded each day during the treatment administration and 7 days after the last administration for all treated subjects (children and adults).

Statistical methods
The prevalence of active trachoma was estimated based on the presence of TF alone. Data were compiled and analysed using EPIINFO V.6 software (Center for Disease Control and Prevention, Atlanta, Georgia, USA). 95% CI were estimated taking into account the composition of sample clusters. Prevalences at different time points were not compared with a statistical test because the methodology for village selection changed over time, and was specifically biased in 2011 and 2013.

RESULTS
Mass treatment campaign using azithromycin 1.5% eye drops
Mass treatment was performed for more than 100,000 inhabitants of the Kololata Health District in 4 communities, representing a coverage of about 90% each year (table 1).

Prevalence surveys in children aged 1–9 years
In all, 2517 children were evaluated in 2008 (year 0) before treatment, 2402 in 2009 (year 1), 2582 in 2010 (year 2), 1933 in 2011 (year 3) 1 year after the last mass treatment and 2484 in 2013 (year 5) 3 years after the last mass treatment. Age and sex of children were similar each year (table 2).

<table>
<thead>
<tr>
<th>Table 1 Mass treatment coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
</tr>
<tr>
<td>First treatment round (2008)</td>
</tr>
<tr>
<td>Second treatment round (2009)</td>
</tr>
<tr>
<td>Third treatment round (2010)</td>
</tr>
</tbody>
</table>
Prevalence before each mass treatment round

In 2008, before the first mass treatment campaign, the prevalence of TF alone was estimated at 24.0% (95% CI 20.7 to 27.5). This dropped significantly to 5.8% (95% CI 4.1 to 8.0) after the first mass treatment and to 3.1% (95% CI 2.0 to 4.9) after the second round, achieving the elimination level of <5%. Regarding TI, the prevalence was significantly reduced from 7.5% (95% CI 5.7 to 10.0) of examined children before the first treatment round to 0.0% (95% CI 0.0 to 0.8) 1 year after second treatment round (table 3).

Impact survey after three rounds of treatment

The impact survey showed a TF prevalence of 2.8% (95% CI 2.2 to 3.7) and a TI prevalence of 0.2% (95% CI 0.0 to 1.3) 1 year after the third (table 4).

Surveillance survey after treatment cessation

The surveillance survey showed a TF prevalence of 5.2% (95% CI 3.6 to 7.2) and a TI prevalence of 1.0% (95% CI 0.6 to 1.4), 3 years after the last administration of treatment (table 4).

Safety of azithromycin 1.5% mass treatment

In this mass population study, more than 100,000 subjects including the youngest children (<1 year old) were treated each year for 3 years. No ocular or systemic serious adverse event related to the study drug was reported in adults and children, during the 3 days of treatment administration and the seven following days. No treatment interruption was required in adults or children. Local and transitory symptoms including blurred vision and burning sensation, following eye drop instillation) occurred in some subjects but were not systematically recorded.

DISCUSSION

In 2008, the District of Kolofata was highly endemic for trachoma, with 24.0% of 1–9 years old children with TF and 7.5% with TI. The prevalence of active trachoma in this district justified the mass treatment of the entire population with 3 yearly rounds of azithromycin as part of the SAFE strategy. This study is the first to use topical azithromycin in mass treatment to reduce the prevalence of active forms of trachoma in an endemic population and included a surveillance survey 3 years after treatment mass cessation. After two annual rounds of mass treatment with topical azithromycin covering more than 90% of the entire population, an estimated TF prevalence of 3.1% was reached, and the WHO objective for elimination of active trachoma (prevalence <5%) was met. This was maintained 1 year after a third annual round, during which children were chosen among the most prevalent villages and among villages never tested. In parallel, the presence of TI was detected in less than 1% of subjects after the second and third annual mass treatments, which is encouraging since TI subjects are those most likely to develop cicatricial complications as the disease progresses.

This study confirms previous results of a randomised clinical trial demonstrating that topical azithromycin 1.5% eye drops were at least as effective as the standard treatment in reducing the prevalence of active trachoma below 5%.

A major concern when implementing a programme for eliminating trachoma is still to determine when to stop antibiotic treatment and preventive interventions and to determine the potential rebound in prevalence of active trachoma after interventions are stopped. As recommended in the WHO guidelines, a surveillance

Table 2 Characteristics of the five surveys

<table>
<thead>
<tr>
<th></th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of selected villages/clusters</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>31</td>
<td>41</td>
</tr>
<tr>
<td>Number of subjects assessed</td>
<td>2517</td>
<td>2402</td>
<td>2582</td>
<td>1933</td>
<td>2484</td>
</tr>
<tr>
<td>Age, years</td>
<td>Mean (SD)</td>
<td>4.2 (2.3)</td>
<td>4.1 (2.3)</td>
<td>4.6 (2.4)</td>
<td>4.4 (2.5)</td>
</tr>
<tr>
<td>Sex</td>
<td>Female, n (%)</td>
<td>1232 (48.9)</td>
<td>1169 (48.7)</td>
<td>1266 (49.0)</td>
<td>977 (50.6)</td>
</tr>
<tr>
<td></td>
<td>Male, n (%)</td>
<td>1285 (51.1)</td>
<td>1233 (51.3)</td>
<td>1316 (51.0)</td>
<td>956 (49.4)</td>
</tr>
</tbody>
</table>

SD, Standard deviation.

Table 3 Prevalence of active trachoma prior to each mass treatment round

<table>
<thead>
<tr>
<th></th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>TF</td>
<td>n, % (95% CI)</td>
<td>603, 24.0 (20.7 to 27.5)</td>
<td>140, 5.8 (4.1 to 8.0)</td>
<td>81, 3.1 (2.0 to 4.9)</td>
</tr>
<tr>
<td>TI</td>
<td>n, % (95% CI)</td>
<td>190, 7.5 (5.7 to 10.0)</td>
<td>14, 0.5 (0.13 to 1.6)</td>
<td>0, 0 (0.0 to 0.8)</td>
</tr>
</tbody>
</table>

TF, trachomatous inflammation—follicular; TI, trachomatous inflammation—intense.
survey should be conducted at least 2 years after the impact
survey to show that elimination targets is maintained in
1–9 years old children, as an indicator of trachoma elimina-
tion.\textsuperscript{26} Three to five years, or five to seven years of
implementation of SAFE may be insufficient to achieve
trachoma elimination as a public health problem in some
endemic regions. Some severely affected districts in Ethio-
pia have been treated for a decade and have still not
achieved the prevalence threshold of 5\% for halting treat-
ment.\textsuperscript{27} In our study, although active trachoma seemed
to be eliminated after three annual rounds of treatment, it
persisted in a few communities after treatment cessa-
tion. Three years after the last round of treatment, the
surveillance survey using a two-stage sample procedure
including the most prevalent villages and villages never
tested before showed a TF prevalence of 5.2\%, just above
the WHO prevalence determined as the threshold neces-
sary for the complete elimination of trachoma as a public
health problem. Although the effectiveness of the SAFE
strategy using oral azithromycin distribution has been
demonstrated in numerous endemic populations world-
wide,\textsuperscript{12} the effect of mass treatment at the village level is
known to be heterogeneous.\textsuperscript{28, 29} In low-endemic coun-
tries such as Gambia, a single oral dose of mass antibiotic
treatment was sufficient to control \emph{C. trachomatis} infection
when combined with environmental conditions, such as
good water supply and sanitation, without re-emergence
of trachoma 5 years after treatment cessation.\textsuperscript{30} How-
ever, in more endemic regions, complete trachoma elimina-
tion in all communities may be difficult to achieve. Lakew \textit{et al}
showed that although trachoma prevalence was lowered
to an average of 2.6\% after four biannual treatments,
prevalence had returned to 25.2\% 2 years after the last
treatment, indicating that if infection is not eliminated at
the community level, it may return.\textsuperscript{29} In Mali, a 3-round
mass treatment with oral azithromycin reduced the pre-
valence of active trachoma from 17\% to less than 5\%, but
3 years later trachoma started to re-emerge.\textsuperscript{31}

Thus, the risk of re-emergence of trachoma once
antibiotic pressure is removed is currently a major concern.\textsuperscript{25}
Factors affecting the success of a Mass Drug Administra-
tion programme have been recently identified using a
mathematical model of disease transmission.\textsuperscript{32} This
included antibiotic treatment-related factors, such as
coverage, dosing and frequency of distribution, and
resistance. Antibiotic mass treatment coverage is an
important issue since untreated individuals may serve
as a source of community reinfection. WHO considered
that coverage of 80\% is acceptable, and increasing
coverage above 90\% in children does not appear to
confer additional benefit.\textsuperscript{33, 34} Nevertheless low coverage
rates (<60\%) of oral azithromycin mass treatment was
reported in some highly endemic districts in Ethiopia.\textsuperscript{35}
This can be due to a low acceptability of the oral azith-
romycin in some regions, in particular because of the
fear of adverse events, as suggested previously.\textsuperscript{36} Oral
azithromycin is generally well tolerated during mass
treatment distribution,\textsuperscript{25} and has been associated with
reduced all-cause and infectious childhood mortality.\textsuperscript{37}
Nevertheless, up to 10\% of people may experience side
effects, primarily gastrointestinal disorders (abdominal
pain, nausea and diarrhoea).\textsuperscript{38} Adverse effects in the first
annual mass treatment round have been considered as a
‘great public health concern’ in some endemic regions
which may compromise acceptability and treatment
coverage.\textsuperscript{35, 36} Moreover, in endemic communities, some
individuals may be suspicious of taking an oral medicine
for an eye disease. By contrast, we confirmed that topical
azithromycin 1.5\% was safe even in the youngest children
of less than 6 months, as previously reported in different
studies.\textsuperscript{15, 39} Thus, topical azithromycin may be more
easily accepted and could be proposed as an alternative
when oral azithromycin is refused or contra-indicated.
We assume that this could improve the coverage in some
districts or communities where the trachoma elimina-
tion or control is difficult. A recent meta-analysis showed
that absence of latrines, dirty faces of children, and no reported use of soap
for washing may be other important factors associated
with active trachoma among children.\textsuperscript{40} In the Kolofata
District, re-emergence was shown in several villages with
impaired access to water due to borehole pump dysfunc-
tion or dry wells during a part of the year. Re-emergence
of active trachoma above 10\% in 1–9 years old children was
also reported in several Kolofata District villages in which
face washing among children was notably deficient.\textsuperscript{41}
As in other endemic regions, while the S and A components
have been widely implemented, evidence and specific
targets are lacking for the F and E components, of which
water, sanitation and hygiene are critical elements.\textsuperscript{5} The
current recommendation for antibiotic mass treatment is
to treat all the district community including infants of less
than 6 months. It is known that the probability of being
infected by \emph{C. trachomatis} is strongly influenced by age.
Children aged less than 1 year have the highest bacterial
load, and thus should be treated.\textsuperscript{42} Oral azithromycin is
not recommended in children under 6 months of age,
and tetracycline ointment is typically used. In contrast,
treatment with 1.5\% azithromycin eye drops is possible
since azithromycin 1.5\% is well tolerated in infants from
1 day of age.\textsuperscript{43} Two times per day administration for 3 days
with topical azithromycin 1.5\% is also more convenient
than tetracycline ointment, which requires two times per
day instillations for 6 weeks.\textsuperscript{44} Thus, topical azithromycin
may be proposed in place of tetracycline ointment to
treat infants of less than 6 months.

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|}
\hline
 & 2011 & 2013 \\
\hline
TF & 54 & 128 & 2.8 (2.2 to 3.7) & 5.2 (3.6 to 7.2) \\
\hline
TI & 4 & 26 & 0.2 (0.0 to 1.3) & 1.0 (0.6 to 1.4) \\
\hline
\end{tabular}
\caption{Prevalence of active trachoma during the follow-up surveillance}
\end{table}

\textsuperscript{TF}, trachomatos inflammation—follicular; \textsuperscript{TI}, trachomatos
inflammation—intense.
Azithromycin 1.5% eye drops have other advantages compared with oral azithromycin. The possibility of inadequate and thus ineffective oral dose, when calculated on the height stick in children, may lead to insufficient dosing which may be an issue especially when the bacterial load is high.\(^2\)\(^5\) In addition, eye drops avoid the potential issue of reconstituting an oral solution in a remote area. The use of topical azithromycin should also substantially reduce the risk of bacterial resistance. By contrast, repeated oral azithromycin mass distribution may be detrimental if it results in the selection of macrolide-resistant pathogens, and there is epidemiological evidence suggesting that pharyngeal carriage of macrolide-resistant \textit{Streptococcus pneumoniae} increases following repeated annual mass treatments with oral azithromycin for trachoma control, as recently reviewed by O’Brien \textit{et al.}\(^5\)\(^4\)\(^5\)

Oral azithromycin is generously donated through the International Trachoma Initiative for trachoma control programmes and topical azithromycin may be a promising alternative to oral azithromycin if treatment units are donated similarly, which was the case in the Kolofata Health District. In addition, beside the costs of the treatment units, a campaign to eliminate trachoma as a public health problem is probably more expensive initially when topical rather than oral azithromycin is used, since the former requires health resources over 3 days and the latter only 1 day. Further studies that take into account both short-term and long-term costs and benefits are necessary to determine the overall cost-effectiveness of topical versus systemic azithromycin mass treatment. To reduce costs in a campaign using topical medication, more community members could be trained to administer the final 2 days of drops; expanding community involvement might have the added benefit of increasing community commitment. Basic training of such community or family eye drop administrators could be done on site on the first day of administration: the health worker would train a member of each family or group of families and that person would administer drops on days 2 and 3. The feasibility and reliability of such a strategy remain to be investigated. In our situation, the administration of topical azithromycin to more than 100 000 inhabitants was successful and logistically and financially similar to other subsidised mass drug and vaccine administration activities held previously in the district.

The study has some limitations including the lack of a control group, meaning a comparison between topical and oral azithromycin mass treatment cannot be made directly. Other components of the SAFE strategy were also applied during the mass treatment campaign, including surgery of entropion-trichiasis, educational activities to promote individual (facial cleanliness) and collective hygiene, and environmental changes. During the mass treatment campaign, the Cameroon government installed borehole water pumps, while the OSF built some wells. However, it is not known to what extent these interventions helped in reducing trachoma prevalence. Persistence and transmission of trachoma is favoured where people live in poverty without safe water, sanitation and proper waste disposal, and the disease may return after antibiotic treatment if these conditions are not changed.\(^3\)\(^4\)\(^1\) Moreover, the clinical grading was based on clinical observations in accordance with the WHO simplified grading system.\(^2\)\(^1\) Specific biological tests using serological and PCR markers may be more reliable for testing ocular TF infection.\(^4\)\(^6\) Furthermore, by selecting one part of the sample from the most prevalent villages of the previous years and the other part from villages never surveyed before, the prevalence of active trachoma in the follow-up surveys (2011 and 2013) was no longer representative of the district level. Finally, standardisation for age as recommended by the recent WHO guidelines in 2018\(^1\)\(^8\) was not possible. Such analysis was not planned at time of data recording, and data for the available census performed in the Kolofata District at that time could not be retrieved.

In conclusion, mass treatment with azithromycin eye drops was shown to be effective to reduce TF to a level ≤5% one year after a 3-round annual mass treatment in an endemic region at the district level. Longitudinal studies in multiple environments using epidemiologically rigorous sampling techniques are needed to ensure that the risk of re-emergence of disease and infection is not more likely than with oral azithromycin. Annual mass treatment of active trachoma with azithromycin 1.5% eye drops is feasible under field conditions, although the cost-effectiveness of topical azithromycin needs to be determined. In the meantime such topical azithromycin treatment could be proposed as an alternative treatment to tetracycline ointment or oral azithromycin (1) for treating young children of less than 6 months, (2) for treating others unable to take oral azithromycin, (3) for mass drug administration where the oral azithromycin donation programme is unavailable and (4) where the population mistrusts oral azithromycin given for an eye condition.

\textbf{Acknowledgements} This study benefited from the expertise of the WHO Prevention of Blindness and Deafness Unit. The Ministry of Public Health of Cameroon placed at our disposal the personnel required for the success of the study. The authors also wish to thank Kolofata’s traditional chiefs and heads of households for their hospitality and participation, and Thierry Radeau for medical writing service.

\textbf{Contributors} AA was the local responsible ophthalmologist in charge of treatment administration and trachoma evaluation; ALB was the study coordinator; EE contributed to the planning and execution of the study; PH was responsible for statistical methodology and for reporting of study results; DR coordinated the medical writing activities; AA, ALB, PB, EE, PH and DR reviewed and approved the final manuscript.

\textbf{Funding} The prevalence surveys were financed by the NGO Ophthalmo Sans Frontières. Laboratoires Théa donated the azithromycin 1.5% eye drops and funded medical writing activities.

\textbf{Competing interests} PH was previously employed at Laboratoires Théa and DR is currently employed at Théa Open Innovation and at Fondation Théa.

\textbf{Patient and public involvement} Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

\textbf{Patient consent for publication} Not required.


